---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-016278"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:40:27.507918+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nektar partners with TrialNet for Phase 2 study of rezpegaldesleukin in type 1 diabetes

## Summary
- TrialNet will conduct a Phase 2 randomized, placebo-controlled trial in ~70 adults and children with new onset stage 3 T1D.
- Nektar supplies rezpegaldesleukin, retains all program rights; TrialNet funds the study via NIH.
- Study aims to preserve beta-cell function using MMTT-measured C-peptide over 12 months; initiation targeted for 2025.
- Rezpegaldesleukin is also in Phase 2b trials for atopic dermatitis (REZOLVE-AD) and alopecia areata (REZOLVE-AA).

## SEC filing metadata
- accession: 0001213900-25-016278
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390025016278/0001213900-25-016278-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390025016278/ea0231907-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-016278
- JSON: https://secwatch.observer/filing/0001213900-25-016278.json
- Plain text: https://secwatch.observer/filing/0001213900-25-016278.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.